Khan, Sajid
Zhang, Xuan http://orcid.org/0000-0001-6062-6708
Lv, Dongwen http://orcid.org/0000-0003-4677-8996
Zhang, Qi
He, Yonghan
Zhang, Peiyi
Liu, Xingui
Thummuri, Dinesh
Yuan, Yaxia
Wiegand, Janet S.
Pei, Jing
Zhang, Weizhou
Sharma, Abhisheak http://orcid.org/0000-0003-0553-4039
McCurdy, Christopher R.
Kuruvilla, Vinitha M.
Baran, Natalia http://orcid.org/0000-0003-0618-4798
Ferrando, Adolfo A.
Kim, Yong-mi
Rogojina, Anna
Houghton, Peter J.
Huang, Guangcun http://orcid.org/0000-0003-1695-1153
Hromas, Robert
Konopleva, Marina
Zheng, Guangrong http://orcid.org/0000-0002-8106-6663
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
Funding for this research was provided by:
NIH
CPRIT
Article History
Received: 11 February 2019
Accepted: 28 October 2019
First Online: 2 December 2019
Competing interests
: S.K., X.Z, Y.H., P.Z., G.Z. and D.Z. are inventors of two pending patent applications for use of BCL-X<sub>L</sub> PROTACs as senolytic and antitumor agents. R.H., G.Z. and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-X<sub>L</sub> PROTACs to treat cancer.